197 related articles for article (PubMed ID: 15146442)
1. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies.
Ferro D; Pignatelli P; Loffredo L; Conti F; Valesini G; D'Angelo A; Violi F
Arthritis Rheum; 2004 May; 50(5):1693-4. PubMed ID: 15146442
[No Abstract] [Full Text] [Related]
2. No increase of beta 2-glycoprotein I levels in patients with antiphospholipid antibodies.
De Benedetti E; Reber G; Miescher PA; de Moerloose P
Thromb Haemost; 1992 Nov; 68(5):624. PubMed ID: 1455413
[No Abstract] [Full Text] [Related]
3. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
Martinez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Garmendia M; Gabriel Erdozain J; Villar I; Aguirre C
Lupus; 2007; 16(10):810-6. PubMed ID: 17895304
[TBL] [Abstract][Full Text] [Related]
4. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Moore GW; Rangarajan S; Savidge GF
Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid antibodies--our experience.
Srikrishna A; Sitalakshmi S; Devi S; Damodar P; Varghese J; Suresh J; Mathew T
Indian J Pathol Microbiol; 2004 Apr; 47(2):174-7. PubMed ID: 16295461
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Viveros ME; Cabiedes J; Reyes E; Cabral AR
Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.
Vayá A; Santaolaria M; Micó L; Calvo J; Oropesa R; Villa P; Todoli J; Simó M; Corella D; Ricart JM
Clin Hemorheol Microcirc; 2008; 40(2):79-87. PubMed ID: 19029633
[TBL] [Abstract][Full Text] [Related]
8. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
[TBL] [Abstract][Full Text] [Related]
9. [The heterogeneity of systemic lupus erythematosus due to the antiphospholipid syndrome].
Alekberova ZS; Nasonov EL; Stoianovich LZ
Ter Arkh; 1992; 64(5):77-9. PubMed ID: 1455383
[No Abstract] [Full Text] [Related]
10. The clinical associations of lupus anticoagulant and anticardiolipin antibodies.
Chogle AR; Buchanan RR
J Assoc Physicians India; 1994 Jul; 42(7):553-9. PubMed ID: 7868526
[No Abstract] [Full Text] [Related]
11. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients.
Formiga F; Mitjavila F; Pac M; Moga I
Lupus; 1997; 6(5):486. PubMed ID: 9229372
[No Abstract] [Full Text] [Related]
12. Lupus anticoagulants and antiphospholipid antibodies monitoring in systemic lupus erythematosus.
Ariano CC; Salmaggi A; Croci D; Lamperti E; Bottero P; Castiglione A; Venegoni E; La Mantia L; Eoli M
Contrib Nephrol; 1992; 99():118-22. PubMed ID: 1458916
[No Abstract] [Full Text] [Related]
13. Antiphospholipid antibody tests: spreading the net.
Bertolaccini ML; Gomez S; Pareja JF; Theodoridou A; Sanna G; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus.
Puurunen M; Vaarala O; Julkunen H; Aho K; Palosuo T
Clin Immunol Immunopathol; 1996 Jul; 80(1):16-22. PubMed ID: 8674235
[TBL] [Abstract][Full Text] [Related]
15. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.
Wong RC; Adelstein S; Gillis D; Favaloro EJ
Semin Thromb Hemost; 2005 Feb; 31(1):39-48. PubMed ID: 15706474
[TBL] [Abstract][Full Text] [Related]
16. [Anticardiolipin antibodies in patients with systemic lupus erythematosus].
Petrović R; Petrović M; Novicić-Sasić D; Damjanov N
Srp Arh Celok Lek; 1994; 122 Suppl 1():98-100. PubMed ID: 18173204
[TBL] [Abstract][Full Text] [Related]
17. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody.
Matsuda J; Saitoh N; Gohchi K; Gotoh M; Tsukamoto M
Am J Hematol; 1994 Sep; 47(1):56-8. PubMed ID: 8042617
[TBL] [Abstract][Full Text] [Related]
18. Neither cell-surface nor soluble CD154 levels are associated with coronary artery disease in systemic lupus erythematosus.
von Feldt JM; Latif S; Genin A; Cron RQ
J Rheumatol; 2008 Feb; 35(2):359-60. PubMed ID: 18260168
[No Abstract] [Full Text] [Related]
19. Revision of the Sapporo criteria for the antiphospholipid syndrome-- coming to grips with evidence and Thomas Bayes?
Lackner KJ; Peetz D; von Landenberg P
Thromb Haemost; 2006 Jun; 95(6):917-9. PubMed ID: 16732366
[No Abstract] [Full Text] [Related]
20. [Primary antiphospholipid syndrome].
Popa A; Voinea L; Pop M; Stana D; Dascalu AM; Alexandrescu C; Ciuluvica R
Oftalmologia; 2008; 52(1):13-7. PubMed ID: 18714484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
